GlassScriptPhysician profile
Zaid Baha
NPI 1447604608
$13,583.14
in general payments reported to CMS, 2019-2025
14 companies · $8,013 in 2025
The $8,013 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2022: $60.48 · 2023: $846 · 2024: $4,395 · 2025: $8,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,572 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,570.00 |
| Food and Beverage | $2,571.88 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,453.20 | 2022-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $4,946.73 | 2023-2025 | Uzedy, Austedo, Austedo Xr |
| Alkermes, INC. | $552.40 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $347.48 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $313.07 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $298.53 | 2023-2025 | Spravato, Invega, Invega Sustenna |
| Indivior INC. | $269.90 | 2023-2024 | Perseris |
| Neurocrine Biosciences, INC. | $144.02 | 2022-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $130.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.70 | 2025 | Trintellix |
| Axsome Therapeutics, INC. | $33.76 | 2023-2024 | Auvelity |
| Uswm, LLC | $23.79 | 2024 | Lucemyra |
| Luye Pharma (USA) LTD. | $15.23 | 2025 | Erzofri Extended-Release |
| Lundbeck LLC | $14.41 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zaid Baha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.